Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of enpatoran for active cutaneous manifestations of lupus on standard therapy
CTR20262380Phase 3Active
- Sponsor
- Merck KGaA
- Start
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of enpatoran in cutaneous lupus erythematosus (CLE), systemic lupus erythematosus (SLE), sponsored by Merck KGaA. Started Jun 2026; status: active.
02
Drugs
enpatoran
03
Conditions
cutaneous lupus erythematosus (CLE)systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on CTR20262380.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262380.